When I went to the Genentech annual stockholders meeting last year
(as a guest as I own no stock) they talked about do a lot of post-marketing surveillance as required by the FDA, but I have heard of little evidence of it.
Once we get a certain number of responses I think we should print them out and send them to the right department at Genentech ie the one in charge of post-marketing surveillance. These are not life-threatening side-effects, but
the data should be collected and dispersed.
Thanks to everyone who has added to the thread so far.
|